Nice | Rivaroxaban for DVT treatment

21st August 2012 by Louise Hudman

This guideline advises that Rivaroxaban can now be considered for use in the treatment of proximal DVT. It is as effective as warfarin, but is more expensive. I suspect we will need to await local approval before use. It doesn’t require monitoring.

It is contraindicated with GFR < 30 and ‘very high blood pressure’ among other things. Use is normally for 3m, though may be needed for longer if there are ongoing risk factors for VTE. It hasn’t really been studied beyond 12m, so use beyond that is of uncertain effectiveness (though is allowed).

Interestingly, there is a higher risk of non-major bleeding with rivaroxaban than on warfarin, though a similar rate of major bleeding.

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


"I have found LocumDeck to be the most helpful and invaluable resource for keeping bookings and accounts. I want to thank you for the wonderful service you provide. Many thanks once again for all the NASGP provides, and particularly for use of the excellent resource LocumDeck has proved to be – something I have recommended to many colleagues who have taken a step to locum work."

Dr Ruth Snowball, GP, Birmingham

Dr Ruth Snowball, GP, Birmingham

See the full list of features within our NASGP membership plans